Peptides / Growth hormone axis

Natural peptide · 70 amino acids · 7,649 Da

IGF-1 (mecasermin)

ApprovedBanned in sport

IGF-1 is a natural growth factor. Its drug form, mecasermin (Increlex), is approved in the US and EU for certain growth disorders in children, and studies in people measured blood sugar, bone and kidney function. PepBank shows 399 results on IGF-1 from 45 studies in people, and 16 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as IGF-1, IGF-I, rhIGF-1, rhIGF-I, Insulin-like growth factor 1, Mecasermin and 2 more

First 40 of 70 amino acids0 changed amino acids

Evidence level: Large trials in people399 of 415 results come from studies in people, including randomized trials.

Results in people

399

96% of 415 results

Results in animals

3% of 415 results

Results in lab cells

under 1% of 415 results

From computer models

0% of 415 results

Overview

IGF-1 (mecasermin) at a glance

What it is	Natural peptide, 70 amino acids
Approval	Approved in the US and EU (Increlex, 2005)
In sport	Banned in sport (WADA S2.3)
Studies	52 studies with results. 46 of them gave IGF-1, with 415 results. 399 in people13 in animals3 in lab cells
Best study in people	Randomized controlled trial with 330 people (2008)
Clinical trials	52 registered: 3 active or planned, 24 with posted results

The science

What is IGF-1?

Native 70-residue insulin-like growth factor 1, with recombinant mecasermin approved for specific childhood growth disorders.

Amino acids in one chain

The history of IGF-1

1986
The oldest paper on IGF-1 in PepBank is from 1986.
1991May
A registered trial of IGF-1 started (NCT00571727).
2005August
FDA approved Increlex for growth failure in children aged 2 years and older with severe primary IGF-1 deficiency, or GH gene deletion with neutralizing antibodies to GH.
2007August
EMA approved Increlex for long-term treatment of growth failure in children and adolescents with severe primary IGF-I deficiency.

IGF-1 (mecasermin) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 70 amino acidsFrom the first amino acid to the last

G1P−ETL5CGA−EL10V−DALQ15FVCG−D20+RGFYF25N+KPTG30YGSSS35+R+RAPQ40TGIV−D45−ECCF+R50SC−DL+R55+RL−EMY60CAPL+K65PA+KSA70

Darker means more water-repelling+ and − show charge in the body

Structure

IGF-1 (mecasermin) is a natural peptide of 70 amino acids, with no ring, 3 disulfide bonds, no changed amino acids.

Formula

C₃₃₁H₅₁₂N₉₄O₁₀₁S₇

Molecular weight

7,649 g/mol

CAS number

68562-41-4

Target

Insulin-like growth factor 1 receptor (gene IGF1R): agonistEvidence: known

Development

Increlex: Eton Pharmaceuticals (current US labeler). Highest phase: past the trial stage (see status).

Identifiers

ChEMBL CHEMBL1201716, UNII 7GR9I2683O, DrugBank DB01277, UniProt P05019

See charge, composition and 3D structure on the Scientific page

The evidence

What IGF-1 studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people399 of 415 results come from studies in people, including randomized trials.

Blood sugar

74 results · 74 in people

In adolescents with IDDM, adding rhIGF-I to insulin therapy reduced HbA1c versus placebo plus insulin therapy. Lancet, 1997

Top results

In adolescents with IDDM, adding rhIGF-I to insulin therapy reduced HbA1c versus placebo plus insulin therapy. (Lancet, 1997)
In type 1 diabetes, added rhIGF-I lowered long-term blood sugar more than intensified insulin alone. (Diabetes care, 1999)
In GH-deficient young adults, rhIGF-I increased glucose production by the liver from baseline. (The Journal of clinical endocrinology and metabolism, 2000)

Growth hormone and growth

66 results · 55 in people · 8 animal · 3 lab

In elderly women, serum IGF-I increased in all groups, including both rhIGF-I groups. The Journal of clinical endocrinology and metabolism, 1995

Top results

In elderly women, serum IGF-I increased in all groups, including both rhIGF-I groups. (The Journal of clinical endocrinology and metabolism, 1995)
In adolescents with IDDM receiving insulin therapy, rhIGF-I did not change circulating IGF-binding protein 1 compared with placebo. (Lancet, 1997)
In children with GH receptor deficiency, rhIGF-I increased growth rate, sustained over therapy. (The Journal of clinical endocrinology and metabolism, 1995)

Bones and joints

52 results · 50 in people · 2 animal

In women with anorexia nervosa, spinal bone density increased more with rhIGF-I than placebo in the factorial analysis. The Journal of clinical endocrinology and metabolism, 2002

Top results

In women with anorexia nervosa, spinal bone density increased more with rhIGF-I than placebo in the factorial analysis. (The Journal of clinical endocrinology and metabolism, 2002)
In women with anorexia nervosa, serum PTH was unchanged in both rhIGF-I groups compared with placebo. (The Journal of clinical endocrinology and metabolism, 1996)
In fasting women, rhIGF-I increased osteocalcin, with higher levels than placebo at treatment end. (The Journal of clinical investigation, 1995)

Metabolism and nutrition

27 results · 27 in people

In GH-deficient young adults, rhIGF-I increased protein synthesis from baseline. The Journal of clinical endocrinology and metabolism, 2000

Top results

In GH-deficient young adults, rhIGF-I increased protein synthesis from baseline. (The Journal of clinical endocrinology and metabolism, 2000)
IGF-I initially did not change beta-hydroxybutyrate in fasted normal men. (The Journal of clinical investigation, 1993)
In healthy adults, rhIGF-I and insulin similarly reduced fat oxidation rates. (The Journal of clinical investigation, 1994)

Weight and appetite

24 results · 21 in people · 3 animal

In elderly women, fat mass decreased in all groups, including both rhIGF-I groups. The Journal of clinical endocrinology and metabolism, 1995

Top results

In elderly women, fat mass decreased in all groups, including both rhIGF-I groups. (The Journal of clinical endocrinology and metabolism, 1995)
In adolescents with IDDM receiving insulin therapy, rhIGF-I did not change body-mass index compared with placebo. (Lancet, 1997)
In children with GH insensitivity, the spleen grew rapidly during early IGF-I treatment. (The Journal of clinical endocrinology and metabolism, 2001)

Kidneys and bladder

20 results · 20 in people

In acute kidney failure, rhIGF-I did not improve kidney filtration more than placebo. Kidney international, 1999

Top results

In acute kidney failure, rhIGF-I did not improve kidney filtration more than placebo. (Kidney international, 1999)
In kidney transplant recipients, day 7 kidney clearance did not differ between IGF‑1 and placebo. (Kidney international, 2003)
In adolescents with IDDM, kidney filtration assessments showed no adverse events during the rhIGF-I trial. (Lancet, 1997)

All 52 IGF-1 studies by area Open the Scientific page

Key IGF-1 studies

Studies in people come first, then studies in animals and in the lab.

People
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial
Sorenson et al. 2008 · Neurology · 330 people · cited by 188
3 results
People
Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group
Lai et al. 1997 · Neurology · 266 people · cited by 245
5 results
People
A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group
Borasio et al. 1998 · Neurology · 183 people · cited by 240
2 results
People
Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure
Hirschberg et al. 1999 · Kidney international · 72 people · cited by 173
11 results
People
Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus
Acerini et al. 1997 · Lancet (London, England) · 53 people · cited by 60
13 results

All 52 IGF-1 (mecasermin) studies

IGF-1 clinical trials

ClinicalTrials.gov lists 52 trials of IGF-1. 3 are active or planned, and 24 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Assessment of Mechanisms of Improved Wound Healing

Phase 2/3completed644 people

Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial

Phase 3completed330 people

Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

Phase 3completed137 people

All 25 IGF-1 (mecasermin) trials

Status and safety

Is IGF-1 approved?

FDA

United States

Approved

Increlex, since 2005.

EMA

European Union

Approved

Increlex, since 2007.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.3.

Yes. Approved in the US and EU (Increlex, 2005). The FDA label for Increlex says: “Growth failure in children aged 2 years and older with severe primary IGF-1 deficiency, or GH gene deletion with neutralizing antibodies to GH” Banned in sport (WADA S2.3).

Laws and labels change, so check the regulator for the current status.

IGF-1 side effects and safety

PepBank has 55 safety results from studies of IGF-1. 55 of them come from studies in people.

Safety results from studies (55)

In ALS patients, significant side effects were similar with low-dose rhIGF-I, high-dose rhIGF-I, and placebo. (Neurology, 1997)
In type 1 diabetes, low blood sugar occurred similarly with added rhIGF-I and insulin alone. (Diabetes care, 1999)
In ALS patients, rhIGF-I appeared safe and well tolerated. (Neurology, 1998)
In acute kidney failure, 12 patients died in each group within 28 days. (Kidney international, 1999)
In adolescents with IDDM, retinal photographs showed no adverse events during the rhIGF-I trial. (Lancet, 1997)
In children with GH receptor deficiency, low blood sugar occurred equally often with rhIGF-I and placebo. (The Journal of clinical endocrinology and metabolism, 1995)
In elderly women, low-dose rhIGF-I was well tolerated. (The Journal of clinical endocrinology and metabolism, 1995)
In women with anorexia nervosa, rhIGF-I was well tolerated. (The Journal of clinical endocrinology and metabolism, 2002)
In children receiving rhIGF-I, low blood sugar occurred before and during therapy. (The Journal of clinical endocrinology and metabolism, 2007)
Postmenopausal women had no low blood sugar during IGF-I treatment. (The Journal of clinical endocrinology and metabolism, 1993)
In patients with type II diabetes, significant side effects occurred in some subjects receiving rhIGF-I. (Diabetes, 1996)
In girls with MECP2 mutations, no evidence of low blood sugar appeared during mecasermin treatment. (Proceedings of the National Academy of Sciences of the United States of America, 2014)
In healthy males, low blood sugar severity did not differ significantly between the first and last IGF-I treatment days. (The Journal of clinical endocrinology and metabolism, 1992)
In girls with anorexia nervosa, rhIGF-1 was well tolerated without low blood sugar. (Bone, 2009)
In children with GH insensitivity receiving IGF-I, no major harmful biochemical changes were observed. (The Journal of clinical endocrinology and metabolism, 2001)
All seven obese diabetic patients stopped rhIGF-I because of side effects. (Diabetes, 1994)
In multiple sclerosis patients, rhIGF-1 was well tolerated with no severe adverse reactions. (Multiple sclerosis, 2002)
Adults with GHRD had no blood sugar levels below the stated hypoglycemia threshold during IGF-I treatment. (The Journal of clinical endocrinology and metabolism, 1993)
In preterm infants receiving the complex, no low blood sugar was recorded. (Pediatric research, 2013)
In type 1 diabetes, the 40/40 dose of rhIGF-I was well tolerated. (Diabetes care, 1999)
In adolescents with IDDM, kidney filtration assessments showed no adverse events during the rhIGF-I trial. (Lancet, 1997)
In adolescents with IDDM, urinary albumin assessments showed no adverse events during the rhIGF-I trial. (Lancet, 1997)
In adolescents with IDDM, routine biochemistry showed no adverse events during the rhIGF-I trial. (Lancet, 1997)
In elderly women, headaches were among the side-effects reported in the GH and high-dose rhIGF-I groups. (The Journal of clinical endocrinology and metabolism, 1995)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
0.05 mg/kg twice daily	Human	human	subcutaneous	2 years	Randomized trial in people · n = 330	Sorenson 2008
0.1 mg/kg/day	Human	human	subcutaneous	9 months	Randomized trial in people · n = 183	Borasio 1998
100 microgram/kg desirable body weight every 12 hours	Human	human	subcutaneous	up to 14 days	Randomized trial in people · n = 72	Hirschberg 1999
100 mg/kg twice a day	Human	human	subcutaneous	6 days	Randomized trial in people · n = 43	Hladunewich 2003
0.10 mg/kg/day	Human	human	Not reported	9 months	Randomized trial in people	Lai 1997
40 microg/kg daily	Human	human	subcutaneous	24 weeks	Randomized trial in people	Acerini 1997
0.05 mg/kg/day and 0.10 mg/kg/day	Human	human	Not reported	9 months	Randomized trial in people · n = 266	Lai 1997
40/40, 80/40 or 80/60 micrograms/kg A.M/P.M	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 223	Thrailkill 1999
30 microg/kg twice daily	Human	human	subcutaneous	9 months	Randomized trial in people · n = 60	Grinspoon 2002
40/40 micrograms/kg A.M/P.M	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 56	Thrailkill 1999
20 or 40 microg/kg daily	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 53	Acerini 1997
100 or 30 micrograms/kg twice daily	Human	human	subcutaneous	6 days	Randomized trial in people · n = 23	Grinspoon 1996
120 micrograms/kg daily	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 17	Guevara-Aguirre 1995
0.015 and 0.060 mg/kg twice daily	Human	human	Not reported	4 weeks	Randomized trial in people · n = 16	Thompson 1995
5 mg twice daily	Human	human	Not reported	Not reported	Randomized trial in people · n = 15	Waters 1996
60 microg/kg twice daily	Human	human	subcutaneous	8 weeks	Randomized trial in people · n = 8	Mauras 2000
0.015 mg/kg twice daily	Human	human	Not reported	4 weeks	Randomized trial in people · n = 6	Thompson 1995
0.060 mg/kg twice daily	Human	human	Not reported	4 weeks	Randomized trial in people · n = 5	Thompson 1995
0.05 mg/kg/day	Human	human	Not reported	9 months	Randomized trial in people	Lai 1997
100 micrograms/kg twice daily	Human	human	subcutaneous	6 days	Randomized trial in people	Grinspoon 1996
30 micrograms/kg twice daily	Human	human	subcutaneous	6 days	Randomized trial in people	Grinspoon 1996
100 micrograms/kg BID	Human	human	subcutaneous	6 days	Randomized trial in people	Grinspoon 1996
30 micrograms/kg BID	Human	human	subcutaneous	6 days	Randomized trial in people	Grinspoon 1996
0.015 mg/kg twice daily	Human	human	Not reported	1 wk	Randomized trial in people	Butterfield 1997
0.03 mg/kg twice daily	Human	human	Not reported	1 wk	Randomized trial in people	Butterfield 1997
0.06 mg/kg twice daily	Human	human	Not reported	1 wk	Randomized trial in people	Butterfield 1997
80/40 or 80/60 micrograms/kg A.M/P.M	Human	human	subcutaneous	12 weeks	Randomized trial in people	Thrailkill 1999
50 mg twice a day	Human	human	subcutaneous	6 months	Trial in people without random groups · n = 7	Frank 2002
60-120 microg/kg twice daily	Human	human	subcutaneous	first year of treatment	Trial in people without random groups · n = 76	Chernausek 2007
0.2, 0.4, and 0.8 micrograms/kg.min	Human	human	infusion	3 h	Trial in people without random groups · n = 35	Boulware 1994
120 micrograms/kg twice daily	Human	human	Not reported	2 yr	Trial in people without random groups · n = 22	Guevara-Aguirre 1997
30-40 mcg/k twice daily	Human	human	Not reported	7-9 days	Trial in people without random groups · n = 20	Misra 2009
30, 60, 120, or 180 micrograms/kg.day	Human	human	subcutaneous	6 days	Trial in people without random groups · n = 18	Ebeling 1993
60 or 15 micrograms/kg b.i.d.	Human	human	subcutaneous	28 days	Trial in people without random groups · n = 16	Ghiron 1995
100 micrograms/kg b.i.d.	Human	human	subcutaneous	6 weeks	Trial in people without random groups · n = 12	Moses 1996
40-120 μg/kg twice daily, then maximum dose	Human	human	Not reported	4-wk MAD and 20-wk OLE	Trial in people without random groups · n = 12	Khwaja 2014
40-120 μg/kg twice daily	Human	human	Not reported	4-wk	Trial in people without random groups · n = 12	Khwaja 2014
Two injections of 0.1 mL Increlex©, 24-h apart	Human	human	Into patellar tendon	Not reported	Trial in people without random groups · n = 12	Hansen 2013
0.03 mg/kg	Human	human	intravenous bolus	5 consecutive days	Trial in people without random groups · n = 12	Lieberman 1992
1.25 micrograms/kg BW.h	Human	human	intraarterial	90 min	Trial in people without random groups · n = 11	Copeland 1994

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official manufacturer label gives a starting dose for indicated childhood growth failure. This record contains no independently supported community regimen.

Reported routines and cautions

Reported regimens

Regimens that community sources report for IGF-1 (mecasermin). Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Label starting dose for indicated childhood growth failureOfficial label dosing of an approved product	subcutaneous injection	0.04 to 0.08 mg/kg per dose	twice daily	Not stated	single source	S1

Community sources

S1Increlex current US prescribing information (opens in a new tab)dailymed.nlm.nih.gov

Gaps

This record contains no independent community-use source for native IGF-I. LR3, DES and MGF require separate records.

Questions and more

Ask a question about IGF-1

The answer links to every study it uses.

What does the evidence say about IGF-1?Is IGF-1 tested in people?Compare with GHRP-6 Compare with HGH (somatotropin)

Sources

Database: PepBank data for IGF-1 (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about IGF-1

IGF-1 (mecasermin)

ApprovedBanned in sport

Also known as IGF-1, IGF-I, rhIGF-1, rhIGF-I, Insulin-like growth factor 1, Mecasermin and 2 more

What it is

Natural peptide, 70 amino acids

Approval

Approved in the US and EU (Increlex, 2005)

In sport

Banned in sport (WADA S2.3)

Studies

52 studies with results. 46 of them gave IGF-1, with 415 results.
399 in people13 in animals3 in lab cells

Best study in people

Randomized controlled trial with 330 people (2008)

Clinical trials

52 registered: 3 active or planned, 24 with posted results

Dose as reported

Class

Species

Route

Duration

Design

Source

0.05 mg/kg twice daily

Human

human

subcutaneous

2 years

Randomized trial in people · n = 330

Sorenson 2008

0.1 mg/kg/day

Human

human

subcutaneous

9 months

Randomized trial in people · n = 183

Borasio 1998

100 microgram/kg desirable body weight every 12 hours

Human

human

subcutaneous

up to 14 days

Randomized trial in people · n = 72

Hirschberg 1999

100 mg/kg twice a day

Human

human

subcutaneous

6 days

Randomized trial in people · n = 43

Hladunewich 2003

0.10 mg/kg/day

Human

human

Not reported

9 months

Randomized trial in people

Lai 1997

40 microg/kg daily

Human

human

subcutaneous

24 weeks

Randomized trial in people

Acerini 1997

0.05 mg/kg/day and 0.10 mg/kg/day

Human

human

Not reported

9 months

Randomized trial in people · n = 266

Lai 1997

40/40, 80/40 or 80/60 micrograms/kg A.M/P.M

Human

human

subcutaneous

12 weeks

Randomized trial in people · n = 223

Thrailkill 1999

30 microg/kg twice daily

Human

human

subcutaneous

9 months

Randomized trial in people · n = 60

Grinspoon 2002

40/40 micrograms/kg A.M/P.M

Human

human

subcutaneous

12 weeks

Randomized trial in people · n = 56

Thrailkill 1999

20 or 40 microg/kg daily

Human

human

subcutaneous

24 weeks

Randomized trial in people · n = 53

Acerini 1997

100 or 30 micrograms/kg twice daily

Human

human

subcutaneous

6 days

Randomized trial in people · n = 23

Grinspoon 1996

120 micrograms/kg daily

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 17

Guevara-Aguirre 1995

0.015 and 0.060 mg/kg twice daily

Human

human

Not reported

4 weeks

Randomized trial in people · n = 16

Thompson 1995

5 mg twice daily

Human

human

Not reported

Randomized trial in people · n = 15

Waters 1996

60 microg/kg twice daily

Human

human

subcutaneous

8 weeks

Randomized trial in people · n = 8

Mauras 2000

0.015 mg/kg twice daily

Human

human

Not reported

4 weeks

Randomized trial in people · n = 6

Thompson 1995

0.060 mg/kg twice daily

Human

human

Not reported

4 weeks

Randomized trial in people · n = 5

Thompson 1995

0.05 mg/kg/day

Human

human

Not reported

9 months

Randomized trial in people

Lai 1997

100 micrograms/kg twice daily

Human

human

subcutaneous

6 days

Randomized trial in people

Grinspoon 1996

30 micrograms/kg twice daily

Human

human

subcutaneous

6 days

Randomized trial in people

Grinspoon 1996

100 micrograms/kg BID

Human

human

subcutaneous

6 days

Randomized trial in people

Grinspoon 1996

30 micrograms/kg BID

Human

human

subcutaneous

6 days

Randomized trial in people

Grinspoon 1996

0.015 mg/kg twice daily

Human

human

Not reported

1 wk

Randomized trial in people

Butterfield 1997

0.03 mg/kg twice daily

Human

human

Not reported

1 wk

Randomized trial in people

Butterfield 1997

0.06 mg/kg twice daily

Human

human

Not reported

1 wk

Randomized trial in people

Butterfield 1997

80/40 or 80/60 micrograms/kg A.M/P.M

Human

human

subcutaneous

12 weeks

Randomized trial in people

Thrailkill 1999

50 mg twice a day

Human

human

subcutaneous

6 months

Trial in people without random groups · n = 7

Frank 2002

60-120 microg/kg twice daily

Human

human

subcutaneous

first year of treatment

Trial in people without random groups · n = 76

Chernausek 2007

0.2, 0.4, and 0.8 micrograms/kg.min

Human

human

infusion

3 h

Trial in people without random groups · n = 35

Boulware 1994

120 micrograms/kg twice daily

Human

human

Not reported

2 yr

Trial in people without random groups · n = 22

Guevara-Aguirre 1997

30-40 mcg/k twice daily

Human

human

Not reported

7-9 days

Trial in people without random groups · n = 20

Misra 2009

30, 60, 120, or 180 micrograms/kg.day

Human

human

subcutaneous

6 days

Trial in people without random groups · n = 18

Ebeling 1993

60 or 15 micrograms/kg b.i.d.

Human

human

subcutaneous

28 days

Trial in people without random groups · n = 16

Ghiron 1995

100 micrograms/kg b.i.d.

Human

human

subcutaneous

6 weeks

Trial in people without random groups · n = 12

Moses 1996

40-120 μg/kg twice daily, then maximum dose

Human

human

Not reported

4-wk MAD and 20-wk OLE

Trial in people without random groups · n = 12

Khwaja 2014

40-120 μg/kg twice daily

Human

human

Not reported

4-wk

Trial in people without random groups · n = 12

Khwaja 2014

Human

human

Into patellar tendon

Not reported

Trial in people without random groups · n = 12

Hansen 2013

0.03 mg/kg

Human

human

intravenous bolus

5 consecutive days

Trial in people without random groups · n = 12

Lieberman 1992

1.25 micrograms/kg BW.h

Human

human

intraarterial

90 min

Trial in people without random groups · n = 11

Copeland 1994

Context

Route

Amount

How often

How long

Agreement

Sources

Label starting dose for indicated childhood growth failureOfficial label dosing of an approved product

subcutaneous injection

0.04 to 0.08 mg/kg per dose

twice daily

Not stated

single source

IGF-1 (mecasermin)

IGF-1 (mecasermin) at a glance

What is IGF-1?

The history of IGF-1

IGF-1 (mecasermin) structure and chemistry

What IGF-1 studies show

Blood sugar

Growth hormone and growth

Bones and joints

Metabolism and nutrition

Weight and appetite

Kidneys and bladder

Key IGF-1 studies

IGF-1 clinical trials

Is IGF-1 approved?

IGF-1 side effects and safety

How people use it

Reported regimens

Community sources

Ask a question about IGF-1

Related peptides

Sources

IGF-1 (mecasermin)

IGF-1 (mecasermin) at a glance

What is IGF-1?

The history of IGF-1

IGF-1 (mecasermin) structure and chemistry

What IGF-1 studies show

Blood sugar

Growth hormone and growth

Bones and joints

Metabolism and nutrition

Weight and appetite

Kidneys and bladder

Key IGF-1 studies

IGF-1 clinical trials

Is IGF-1 approved?

IGF-1 side effects and safety

How people use it

Reported regimens

Community sources

Ask a question about IGF-1

Related peptides

Sources